|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
215 a.a.
|
|
|
|
|
|
|
|
|
|
|
212 a.a.
|
|
|
|
|
|
|
|
|
|
|
194 a.a.
|
|
|
|
|
|
|
|
|
|
|
215 a.a.
|
|
|
|
|
|
|
|
|
|
|
213 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
|
|
Key reference
|
|
|
Title
|
|
Antibody evasion by the p.1 strain of sars-Cov-2.
|
|
|
Authors
|
|
W.Dejnirattisai,
D.Zhou,
P.Supasa,
C.Liu,
A.J.Mentzer,
H.M.Ginn,
Y.Zhao,
H.M.E.Duyvesteyn,
A.Tuekprakhon,
R.Nutalai,
B.Wang,
C.López-Camacho,
J.Slon-Campos,
T.S.Walter,
D.Skelly,
S.A.Costa clemens,
F.G.Naveca,
V.Nascimento,
F.Nascimento,
C.Fernandes da costa,
P.C.Resende,
A.Pauvolid-Correa,
M.M.Siqueira,
C.Dold,
R.Levin,
T.Dong,
A.J.Pollard,
J.C.Knight,
D.Crook,
T.Lambe,
E.Clutterbuck,
S.Bibi,
A.Flaxman,
M.Bittaye,
S.Belij-Rammerstorfer,
S.C.Gilbert,
M.W.Carroll,
P.Klenerman,
E.Barnes,
S.J.Dunachie,
N.G.Paterson,
M.A.Williams,
D.R.Hall,
R.J.G.Hulswit,
T.A.Bowden,
E.E.Fry,
J.Mongkolsapaya,
J.Ren,
D.I.Stuart,
G.R.Screaton.
|
|
|
Ref.
|
|
Cell, 2021,
184,
2939.
[DOI no: ]
|
|
|
PubMed id
|
|
|
|
|
|
Abstract
|
|
|
Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from
early isolates. However, new strains have emerged with multiple mutations,
including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7 from the UK
(12, 10, and 9 changes in the spike, respectively). All have mutations in the
ACE2 binding site, with P.1 and B.1.351 having a virtually identical triplet
(E484K, K417N/T, and N501Y), which we show confer similar increased affinity for
ACE2. We show that, surprisingly, P.1 is significantly less resistant to
naturally acquired or vaccine-induced antibody responses than B.1.351,
suggesting that changes outside the receptor-binding domain (RBD) impact
neutralization. Monoclonal antibody (mAb) 222 neutralizes all three variants
despite interacting with two of the ACE2-binding site mutations. We explain this
through structural analysis and use the 222 light chain to largely restore
neutralization potency to a major class of public antibodies.
|
|
|
Secondary reference #1
|
|
|
Title
|
|
Antibody evasion by the brazilian p.1 strain of sars-
|
|
|
Authors
|
|
W.Dejnirattisai,
D.Zhou,
P.Supasa,
C.Liu,
A.J.Mentzer,
H.My.Zhao,
H.M.Duyvesteyn,
A.Tuekprakhon,
R.Nutalai,
B.Wang,
G.C.Paesen,
C.Lopez-Camacho,
J.Slon-Campos,
T.S.Walter,
D.Skelly,
S.A.C.Clemens,
F.G.Naveca,
V.Nascimento,
F.Nascc.Dold,
R.Levin,
T.Dong,
A.J.Pollard,
J.C.Knight,
D.Crook,
T.Lambe,
E.Clutterbuck,
S.Bibi,
A.Flaxman,
M.Bittaye,
S.Belij-Rammerstorfer,
S.Gilbert,
M.W.Carroll,
P.Klenerme.Barnes,
S.J.Dunachie,
N.G.Paterson,
M.A.Williams,
D.R.Hr.J.G.Hulswit,
T.A.Bowden,
E.E.Fry,
J.Mongkolsapaya,
J.Re.
|
|
|
Ref.
|
|
biorxiv ...
|
|
|
|
|
|
|
